Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Mugen1996on Jan 10, 2011 8:58pm
283 Views
Post# 17951226

RE: san francisco

RE: san franciscoTakesguts, your posts are always appreciated and useful...

The new presentation is currently available on TH's website
https://www.theratech.com/docs/en/corpo/2011_01_10_Thera_CP2011_VFF.pdf

I don't know if you have been following the trading activity since FDA approval, but the house position seems to indicate one or many big holders have been trying to get out. 

222 JP Morgan : bought 0  sold 1,152,600
39 Merrill Lynch : bought 186,300 sold 1,577,900

Both houses seems to be sellers on a daily basis for the past 2 months, capping the SP.  I know Stewardship Partners Councel has 6M TH shares, do you thnk this major institution is currently trying to move to another story.  If so they are not half way done...

I wonder if TH is going to annonce their Europe partnership and new indication anytime soon.  This stock needs something fresh (PII results)?

THanks
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities